196 related articles for article (PubMed ID: 31770139)
1. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
Kinoshita Y; Sakurai Y; Takabayashi N; Kudou K; Araki T; Miyagi T; Iwakiri K; Ashida K
Clin Transl Gastroenterol; 2019 Nov; 10(11):e00101. PubMed ID: 31770139
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Kinoshita Y; Sakurai Y; Shiino M; Kudou K; Nishimura A; Miyagi T; Iwakiri K; Umegaki E; Ashida K
Curr Ther Res Clin Exp; 2016; 81-82():1-7. PubMed ID: 28119763
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Fass R; Vaezi M; Sharma P; Yadlapati R; Hunt B; Harris T; Smith N; Leifke E; Armstrong D
Aliment Pharmacol Ther; 2023 Nov; 58(10):1016-1027. PubMed ID: 37750406
[TBL] [Abstract][Full Text] [Related]
4. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease.
Dent J; Kahrilas PJ; Hatlebakk J; Vakil N; Denison H; Franzén S; Lundborg P
Am J Gastroenterol; 2008 Jan; 103(1):20-6. PubMed ID: 18184117
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
[TBL] [Abstract][Full Text] [Related]
6. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Oshima T; Igarashi A; Nakano H; Deguchi H; Fujimori I; Fernandez J
J Clin Gastroenterol; 2022 Jul; 56(6):493-504. PubMed ID: 35470298
[TBL] [Abstract][Full Text] [Related]
7. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
9. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
10. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.
Kim SH; Cho KB; Chun HJ; Lee SW; Kwon JG; Lee DH; Kim SG; Jung HY; Kim JW; Lee JS; Park H; Choi SC; Jee SR; Kim HS; Ko KH; Park SJ; Lee YC; Park SH; Kim AR; Kim EJ; Park HW; Kim BT; Song GS
Aliment Pharmacol Ther; 2021 Aug; 54(4):402-411. PubMed ID: 34227708
[TBL] [Abstract][Full Text] [Related]
13. VONOPRAZAN IS EFFICACIOUS FOR TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL.
Laine L; Spechler S; Yadlapati R; Schnoll-Sussman F; Smith N; Leifke E; Harris T; Hunt B; Fass R; Katz P
Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38750866
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
[TBL] [Abstract][Full Text] [Related]
15. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
Vaezi MF; Fass R; Vakil N; Reasner DS; Mittleman RS; Hall M; Shao JZ; Chen Y; Lane L; Gates AM; Currie MG
Gastroenterology; 2020 Jun; 158(8):2093-2103. PubMed ID: 32092310
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
Karkon Varnosfaderani S; Hashem-Dabaghian F; Amin G; Bozorgi M; Heydarirad G; Nazem E; Nasiri Toosi M; Mosavat SH
J Integr Med; 2018 Mar; 16(2):126-131. PubMed ID: 29526236
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.
Uemura N; Inokuchi H; Serizawa H; Chikama T; Yamauchi M; Tsuru T; Umezu T; Urata T; Yurino N; Tanabe S; Yoshida T; Kawamura S; Murakami A; Yamamoto M; Chiba T
J Gastroenterol; 2008; 43(9):670-8. PubMed ID: 18807128
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
Hongo M; Kinoshita Y; Haruma K
J Gastroenterol; 2008; 43(6):448-56. PubMed ID: 18600389
[TBL] [Abstract][Full Text] [Related]
19. Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial.
Limsrivilai J; Charatcharoenwitthaya P; Pausawasdi N; Leelakusolvong S
Am J Gastroenterol; 2016 Feb; 111(2):217-24. PubMed ID: 26753892
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Kinoshita Y; Ashida K; Hongo M;
Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
